Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formula ##STR00001## wherein m is 0, 1, 2, 3 or 4; each X is independently selected from the group consisting of hydrogen, halo, cyano, nitro, OCF.sub.3, hydroxy, amino, carboxyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, haloalkyl, alkoxy, alkoxycarbonylalkyl, hydroxycarbonylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkylalkyl, R.sup.1O, R.sup.1R.sup.2N, R.sup.1OCO, R.sup.1CO, R.sup.1R.sup.2NCO, R.sup.1R.sup.2NCONR.sup.2a, R.sup.1OCONR.sup.2a, R.sup.1CONR.sup.2a, R.sup.1S, R.sup.1SO, R.sup.1SO.sub.2, R.sup.1R.sup.2NSO.sub.2, R.sup.1R.sup.2NSO.sub.2NR.sup.2a, and R.sup.1SO.sub.2NR.sup.2a; R.sup.1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R.sup.2 and R.sup.2a are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n is 1, 2, or 3; W is O or H,R.sup.3; R.sup.3 is hydrogen or hydroxyl; Ar is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group; Q is hydrogen, F, or hydroxyl. In addition, a method for using these compounds to treat diseases associated with abnormal or mineral homeostasis is also provided.